China has started granting licenses with lengthier terms to allow European companies to obtain critical minerals, European Commission's trade chief Maros Sefcovic says https://t.co/AR3mbuBV8O https://t.co/9Y0LH823pw ...

Most AI was trained by scraping content without permission, attribution, or payment.The Sui Stack enables a licensing layer where creators get compensated and users get AI built on verified, rights-respecting data.A fairer system for everyone.Read on 👇https://t.co/gaPnpQ3WCj ...

The three-year licensing deal will let users generate videos of more than 200 Disney, Marvel, Star Wars and Pixar characters. ...

The UAE has officially enacted Federal Decree No. 6 of 2025, bringing DeFi, Web3, stablecoin protocols, DEXs, and cross-chain bridges under the supervision of the central bank for the first time. Effective since September 2025, the regulation requires projects engaged in payments, custody, lending, or investment services to obtain proper licensing by September 2026, or face fines of up to AED 1 billion (about $272 million) and potential criminal penalties. https://t.co/tQq3u0a6Yv ...

Warner Music Moves From Litigation to Licensing With Udio► https://t.co/kiXWrDh3Cb https://t.co/kiXWrDh3Cb ...

Financial Data and Key Metrics Changes - Net licensing revenues for Q3 2025 were $1.1 million, down from $1.5 million in Q3 2024, primarily due to cautious consumer spending and lower performance in the Halston license [12] - Year-to-date net licensing revenues were $3.8 million, compared to $6.5 million for the same period last year, largely due to the divestiture of the Lori Goldstein brand [12] - The company reported a net loss of approximately $7.9 million for Q3 2025, an improvement from a net loss of $9.2 million in Q3 2024 [17] - Adjusted EBITDA for Q3 2025 was approximately negative $650,000, representing a 38% year-over-year improvement from negative $1 million in Q3 2024 [18] Business Line Data and Key Metrics Changes - Direct operating costs for Q3 2025 were $2.2 million, down 23% from the prior year quarter, and year-to-date direct operating costs were $6.3 million, a decrease of 36% [12][13] - The company generated an adjusted EBITDA loss of $653,000 in Q3, which is a $400,000 improvement over Q3 2024 [10] Market Data and Key Metrics Changes - The company is experiencing a shift in its core business from linear TV to digital streaming and social commerce, with TikTok Shops surpassing eBay in quarterly volume [7] - The social media reach across the brand portfolio is now 46 million, with a target of reaching 100 million followers by 2026 [8] Company Strategy and Development Direction - The company is focusing on leveraging new business opportunities with UTG, including sourcing products for retail partners and potential acquisitions [6][7] - New influencer brands have diversified product categories into food, kitchen, home, and pet products, with a shift towards domestic production [8] - The company is cautious about Q4 2025 due to tariff impacts on QVC, HSN, and licensees [9] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for transformative transactions and the ability to capitalize on changes in the market [7] - The company is working to resolve issues related to the Halston brand and expects growth in 2026 [10][11] - Management highlighted the importance of top-line royalty revenue and the potential for significant asset value in the company's IP [46] Other Important Information - The company closed a $2 million net equity offering in Q3 2025, with part of the proceeds used to pay down loans [6] - As of September 30, 2025, the company had stockholders' equity of approximately $17 million and unrestricted cash of approximately $1.5 million [20] Q&A Session Summary Question: Importance of hiring Olin Lancaster as Chief Revenue Officer - Management emphasized the significance of the hire, noting Lancaster's extensive experience and the potential for growth with new influencer brands [22] Question: Mitigating tariff impacts with domestic products - Management discussed the strategic focus on domestic sourcing for food and pet products to reduce tariff risks [23][24] Question: Resolution of disruptions with SeaWonder and Christie - Management confirmed that the issues have been resolved, including vendor changes and programming challenges [28] Question: Updates on product roadmap and brand rollouts - Management indicated that new products will start hitting the market in Q1 2026, with a focus on food products and pet accessories [31] Question: Revenue ramp expectations for the next 12 months - Management outlined a roadmap for launching five new influencer-led brands to drive revenue growth into 2026 [39][40] Question: Potential revenue outlook for 2026 - Management refrained from providing specific guidance but referenced analyst reports for potential revenue expectations [45] Question: Long-term revenue targets - Management reiterated the potential for significant royalty income from new brands, emphasizing the global opportunities with influencers [49]

Core Insights - Moberg Pharma AB has entered into an exclusive licensing agreement with Karo Healthcare AB for the commercialization of MOB-015 (Terclara®) in Europe, covering 19 European markets [1][2][11] - The partnership aims to leverage the established Lamisil® brand for a coordinated launch across key EU markets, enhancing market presence and distribution capabilities [3][4][9] Market Opportunity - The agreement encompasses a total population of approximately 500 million people, including major EU countries and the UK, providing significant market potential for MOB-015 [2] - Karo Healthcare will handle marketing, distribution, and sales, allowing Moberg Pharma to focus on other territories, particularly the U.S. [10] Product Details - MOB-015/Terclara® is a next-generation topical formulation of terbinafine, designed to treat nail fungus with a mycological cure rate of 76% in registration studies, comparable to oral treatments [6] - The product aims to address the risks associated with oral treatments, such as drug interactions and liver damage, by providing a safer topical alternative [6] Regulatory and Launch Strategy - The use of the Lamisil® brand for MOB-015 requires approval from national health authorities, which will influence the timing of the product launch [7] - Both companies plan to initiate the launch as soon as possible and will also work to expand marketing authorizations to additional countries [8] Strategic Partnership - Karo Healthcare, backed by KKR, has a strong commercial presence in Europe and established distribution channels, enhancing the product's market entry [9][10] - The collaboration is expected to accelerate Moberg Pharma's commercial expansion and establish MOB-015/Terclara® as a market leader in nail fungus treatment across Europe [11]

Regulatory Landscape - ASIC (澳大利亚证券与投资委员会) 指出比特币不是金融产品 [1] - 仅交易比特币的交易所可免于许可 [1] - 稳定币、wrapped tokens（封装代币）和tokenized securities（代币化证券）需要在 6 月 30 日前获得许可 [1] Industry Implications - 行业对监管明确性表示欢迎 [1] - 行业指出存在瓶颈、专业知识有限、银行准入和保险缺口等问题 [1] - 合规性成为一项后勤挑战 [1]

Hong Kong lawmakers on Wednesday passed a ride-hailing service bill requiring platforms such as Uber to be licensed https://t.co/1PFjkzUO2p ...

💥BREAKING:🇦🇪 ByBit becomes the first licensed crypto exchange in the UAE. https://t.co/kV5UesxDry ...